Search clinical trials for: Darifenacin

Total 25 results

Kwang Dong Pharmaceutical co., ltd.

Completed

A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

Overactive Bladder

Korea, Republic of
Novartis
Procter and Gamble

Completed

Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects

Healthy

India
Bayer

Completed

Post Marketing Surveillance Study on Emselex After Launch in Germany

Overactive Bladder

Germany
Bayer

Terminated

Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

Multiple Sclerosis | Overactive Detrusor

Germany
Cognitive Research Corporation
Novartis Pharmaceuticals

Withdrawn

Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness

Nocturia
Bayer

Completed

FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period (FREEDOM)

Overactive Bladder

South Africa
McGill University
Université de Montréal

Not yet recruiting

A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

Amyotrophic Lateral Sclerosis

Canada
US Department of Veterans Affairs

Completed

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

Overactive Bladder | Parkinson's Disease

United States
Toronto Rehabilitation Institute
Ontario Neurotrauma Foundation

Completed

Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

Spinal Cord Injury | Neurogenic Detrusor Overactivity

Canada
Novartis

Completed

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

Overactive Bladder Syndrome

United States
University of Missouri-Columbia

Terminated

Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain

Overactive Bladder | Renal Colic | Pain, Postoperative

United States
Novartis
Procter and Gamble

Completed

Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder

Overactive Bladder

United States
Novartis
Procter and Gamble

Completed

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Overactive Bladder (OAB)

United States
Novartis

Completed

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

Overactive Bladder Syndrome

United States
Astellas Pharma Singapore Pte. Ltd.

Completed

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Overactive Bladder (OAB)

Korea, Republic of, Australia
Novartis
Procter and Gamble

Completed

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

Urinary Incontinence

United States
Novartis
Procter and Gamble

Completed

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

Healthy

United States
Universidad de Valparaiso
Recalcine (GynoPharm)

Completed

Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women

Overactive Bladder

Chile
Center for Clinical Pharmacology Research Bdbeq...
Laboratorio Elea Phoenix S.A.

Unknown

Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.

Bioequivalency

Uruguay
Warner Chilcott

Terminated

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

United States, Colombia
Novartis
Procter and Gamble

Completed

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

Healthy

United States
Astellas Pharma Singapore Pte. Ltd.

Completed

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Overactive Bladder (OAB)

Korea, Republic of, Taiwan
GlaxoSmithKline

Completed

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Canada
Novartis

Completed

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

Healthy Volunteers

United States
Center for Clinical Pharmacology Research Bdbeq...
Laboratorio Elea Phoenix S.A.

Unknown

Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.

Bioequivalency

Uruguay

3

Subscribe